Cambridge Cognition Holdings plc has expanded its partnership with Actinogen Medical Limited for the phase 2b/3 XanaMIA Alzheimer’s disease trial. Building on the successful integration of Cambridge ...

Oxford Drug Design, the Oxford-based AI drug discovery company, has announced further in vivo validation for its ...

Owlstone Medical has announced a first close of $27 million (circa £22 million) in its Series E financing round. The round ...

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

Pheno Therapeutics Limited has received clinical trial authorisation (CTA) from the UK’s MHRA for its lead candidate, PTD802.

Gilead Sciences and LEO Pharma have announced a strategic partnership to advance LEO Pharma’s oral STAT6 program. This ...

AI is poised to significantly lower pharmaceutical R&D costs through efficient drug discovery, optimised clinical trials, and ...

The National Institute for Health and Care Excellence (NICE) has given a positive recommendation for Lynparza (olaparib) for ...

Sequana Medical NV has announced the US FDA approval of its Alfapump system for treating recurrent or refractory ascites due ...

Prostate cancer resistant to hormone therapy could soon have a new treatment option. The Institute of Cancer Research (ICR), ...

Merck has launched the beta version of M-Trust, a pioneering cyber-physical trust platform, at CES 2025 to tackle product ...

Kearney Urology Center has reported a 50% reduction in biopsies since adopting EpiSwitch PSE, a new accurate blood test for ...